Carlsmed (NASDAQ:CARL) Shares Up 7.8% – Should You Buy?

Carlsmed, Inc. (NASDAQ:CARL – Get Free Report)’s stock price traded up 7.8% on Monday. The company traded as high as $18.22 and last traded at $18.4550. 43,340 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 135,142 shares. The stock had previously closed at $17.12.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CARL. Wall Street Zen raised shares of Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Needham & Company LLC lifted their price target on Carlsmed from $17.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, November 11th. BTIG Research upped their price target on Carlsmed from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Carlsmed in a research note on Wednesday, November 4th. Finally, Truist Financial raised their price objective on Carlsmed from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, November 11th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Carlsmed presently has a consensus rating of “Moderate Buy” and an average price target of $22.00.

Check Out Our Latest Stock Report on CARL

Carlsmed Price Performance

The company has a current ratio of 5.79, a quick ratio of 5.62 and a debt-to-equity ratio of 0.20. The firm has a market cap of $476.86 million, a P/E ratio of -11.76 and a beta of 1.97. The company has a fifty day moving average price of $14.97 and a two-hundred day moving average price of $12.58.

Carlsmed (NASDAQ:CARL – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.08. Carlsmed had a negative net margin of 55.82% and a negative return on equity of 42.42%. The company had revenue of $21.55 million during the quarter. Equities analysts anticipate that Carlsmed, Inc. will post -1.53 earnings per share for the current year.

Hedge Funds Weigh In On Carlsmed

A number of institutional investors have recently modified their holdings of CARL. Deutsche Bank AG bought a new position in Carlsmed in the 2nd quarter worth approximately $106,000. Bank of America Corp DE purchased a new position in Carlsmed during the second quarter valued at $108,000. Entropy Technologies LP purchased a new position in Carlsmed in the third quarter worth about $160,000. Alpine Woods Capital Investors LLC bought a new position in shares of Carlsmed during the second quarter valued at $161,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Carlsmed in the second quarter worth $181,000.

Carlsmed Company Profile

(Get Free Report)

Carlsmed, Inc. is a medical technology company focused on personalized solutions for spine surgery. Its technology uses patient-specific planning and implant design to help surgeons plan spinal-fusion procedures. The company’s products include aprevo®, a line of patient-specific interbody implants made using 3D printing. Carlsmed’s platform is designed to use a patient’s imaging and surgical plan to tailor implant geometry and support alignment goals. Founded in 2018 and based in Carlsbad, California, Carlsmed serves the U.S. market.

Recommended Stories

Receive News & Ratings for Carlsmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carlsmed and related companies with MarketBeat.com's FREE daily email newsletter.